Title
Category
Credits
Event date
Cost
Improving Standards of Care in Type 2 Diabetes with Chronic Kidney Disease: Integrating the Non-Steroidal Mineralocorticoid Antagonist Class in Cardiorenal Medicine
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
Like a Game of Chess, Every Move Matters: The Role of Antibodies in the Myasthenia Gravis Treatment Landscape
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
Advances in Diagnosis of Alzheimer Disease and Emerging Treatment Targets
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.
Treatment Challenges and the Hope of Emerging Therapies in Early-Stage Alzheimer Disease
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer an overview of best practices for managing early-stage Alzheimer disease as well as a look at the future.
Diagnosing and Treating Insomnia in Adults and Older Adults
  • Sleep
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Rosenberg and Krystal identify key steps in the diagnosis and treatment of insomnia disorder.
Optimizing Treatment for Insomnia
  • Sleep
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Dr Krystal describes a new paradigm for managing insomnia in which clinicians can select interventions that best target the sleep problem of each patient. The result is an improved risk-benefit ratio.
Patient-Centered Treatment Strategies to Improve Outcomes in Schizophrenia
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.
Epilepsy Seizure Clusters: Therapeutic Advances and Emergency Plans
  • Anticonvulsants
  • Epilepsy
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Seizure clusters take a toll on patients’ emotional wellbeing, work, and quality of life. Learn from experts about new rescue treatments.
New Options for Rescue Treatment in Individuals With Epilepsy Seizure Clusters
  • Anticonvulsants
  • Epilepsy
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Detyniecki and Penovich identify the need for emergency seizure response plans and the new rescue treatment options that may easily be used by patients with epilepsy and their caregivers.
Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.

Pages